Provided by Tiger Trade Technology Pte. Ltd.

Harmony Biosciences Holdings, Inc.

37.97
+0.50001.33%
Volume:176.00K
Turnover:6.66M
Market Cap:2.19B
PE:11.99
High:38.18
Open:37.39
Low:37.39
Close:37.47
52wk High:40.93
52wk Low:25.52
Shares:57.60M
Float Shares:44.56M
Volume Ratio:0.26
T/O Rate:0.39%
Dividend:- -
Dividend Rate:- -
EPS(TTM):3.17
EPS(LYR):2.56
ROE:25.93%
ROA:13.20%
PB:2.62
PE(LYR):14.85

Loading ...

Jeffrey M. Dayno, President and CEO, Reports Disposal of Harmony Biosciences Holdings Inc. Common Shares

Reuters
·
Dec 18

BRIEF-Beacon Biosignals Announces Partnership With Harmony Biosciences

Reuters
·
Dec 16

Harmony Biosciences Partners with Beacon Biosignals to Advance EEG-Based Sleep Disorder Trials

Reuters
·
Dec 16

Beacon Biosignals Announces Partnership With Harmony Biosciences to Advance Objective Clinical Endpoints in Hypersomnia Conditions Through Quantitative Eeg

THOMSON REUTERS
·
Dec 16

Harmony Biosciences CFO Sandip Kapadia Reports Disposal of Common Shares

Reuters
·
Dec 10

Harmony Biosciences Reports Promising Phase 3 Data for EPX-100 in Dravet Syndrome

Reuters
·
Dec 08

Harmony Biosciences (HRMY) Is Up 7.6% After GR Pitolisant Bioequivalence Win and Patent Runway Push

Simply Wall St.
·
Dec 05

Harmony Biosciences Unveils New Phase 3 ARGUS Trial Data on EPX-100 for Dravet Syndrome

Reuters
·
Dec 02

Mizuho Raises Price Target on Harmony Biosciences Holdings to $46 From $39, Keeps Outperform Rating

MT Newswires Live
·
Dec 01

Harmony Biosciences : Mizuho Raises Target Price to $46 From $39

THOMSON REUTERS
·
Dec 01

Harmony Biosciences Holdings (HRMY) Is Up 6.8% After Positive Pitolisant Study Results Are Patent Hopes Justified?

Simply Wall St.
·
Nov 28

Harmony Biosciences CFO Sandip Kapadia Reports Sale of Common Shares

Reuters
·
Nov 26

Positive Outlook on Harmony Biosciences Holdings: Promising Pipeline Developments and Revenue Growth Potential

TIPRANKS
·
Nov 25

BUZZ- Harmony Biosciences jumps as co announces positive results from sleep disorder drug study

Reuters
·
Nov 24

Harmony Biosciences Price Target Maintained With a $42.00/Share by Needham

Dow Jones
·
Nov 24

Promising Developments and Upcoming Catalysts Drive Buy Rating for Harmony Biosciences

TIPRANKS
·
Nov 24

Harmony Biosciences to Submit NDA for Narcolepsy Treatment Following Trial Results

MT Newswires Live
·
Nov 24

Harmony Biosciences Shares Rise 2% Premarket After Co Announces Positive Results From Sleep Disorder Drug Study

THOMSON REUTERS
·
Nov 24

Harmony Biosciences: New Drug Application to Be Submitted in Early 2026; Target Pdufa in Q1 2027

THOMSON REUTERS
·
Nov 24

Harmony Biosciences - No New Safety Issues Reported for Pitolisant Gr

THOMSON REUTERS
·
Nov 24